Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
65,070,787
-
Share change
-
+540,497
-
Total reported value
-
$76,138,155
-
Put/Call ratio
-
9.1%
-
Price per share
-
$1.17
-
Number of holders
-
99
-
Value change
-
+$641,868
-
Number of buys
-
46
-
Number of sells
-
29
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q4 2022
As of 31 Dec 2022,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,070,787 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, VANGUARD GROUP INC, Defender Capital, LLC., BlackRock Inc., Laurion Capital Management LP, Prescott General Partners LLC, RAFFLES ASSOCIATES LP, GEODE CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
99
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.